ArticleNeurology and therapy2024

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study.

Barry A Singer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.